Intellectual Property Licensing
•126 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (126)
%
| Company | Market Cap | Price |
|---|---|---|
|
Disney monetizes its IP through broad IP licensing across consumer products and media.
|
$196.30B |
$109.19
-2.10%
|
|
Intellectual Property Licensing captures monetization of Sony’s IP across media and entertainment assets.
|
$174.30B |
$28.57
-6.54%
|
|
Synopsys licenses IP cores and silicon IP to customers.
|
$75.93B |
$489.36
+2.63%
|
|
EA leverages and monetizes its IP across games and media, consistent with intellectual property licensing.
|
$50.16B |
$200.02
-0.01%
|
|
Nokia Technologies generates recurring IP licensing revenue from its portfolio of intellectual property.
|
$29.86B |
$5.32
+0.38%
|
|
Intellectual Property Licensing reflects ownership and licensing of organ-tech IP (e.g., collaborations with 3D Systems).
|
$19.85B |
$440.00
-1.27%
|
|
Licensing of polyolefin process technologies and catalysts constitutes IP licensing.
|
$14.43B |
$44.91
-5.59%
|
|
Licensing of intellectual property across products and media is a core Hasbro strategy.
|
$9.94B |
$70.95
-5.39%
|
|
Intellectual Property Licensing covers licensing of Morningstar’s IP/data assets to customers and partners.
|
$9.52B |
$225.34
-1.22%
|
|
Pearson monetizes intellectual property and AI/IP assets through licensing arrangements with customers and partners.
|
$9.03B |
$14.11
|
|
InterDigital's core revenue derives from Intellectual Property Licensing, i.e., licensing its foundational wireless, video, and AI technologies under an IP-as-a-service model.
|
$8.82B |
$339.90
-2.49%
|
|
QuantumScape monetizes its technology and IP through licensing agreements and royalties.
|
$8.22B |
$14.70
-2.65%
|
|
Lucid monetizes technology via Intellectual Property Licensing to Aston Martin and other OEMs.
|
$7.01B |
$22.98
+1.55%
|
|
MINISO develops proprietary IP (e.g., Yu Yu Chan) and engages in IP licensing to expand product offerings (Intellectual Property Licensing).
|
$6.60B |
$21.25
-5.72%
|
|
Mattel monetizes IP via licensing to product manufacturers, media, and other partners.
|
$5.52B |
$17.10
-5.84%
|
|
The company monetizes its technology via licensing and royalties (e.g., INVEGA SUSTENNA collaboration and VUMERITY royalties).
|
$5.15B |
$31.21
-0.54%
|
|
Ligand monetizes its intellectual property through licensing arrangements, forming the core of its asset-light royalty business model.
|
$3.43B |
$177.73
-2.16%
|
|
Company monetizes and licenses intellectual property (IP) and partnerships internationally.
|
$2.78B |
$50.63
-4.42%
|
|
Licensing division represents a material IP/software licensing revenue stream post Cylance divestiture.
|
$2.66B |
$4.48
-7.63%
|
|
Intellectual Property Licensing: licensing of IP data/assets (Derwent IP, IPfolio) to customers.
|
$2.55B |
$3.59
-0.55%
|
|
Cogent has a strategic intellectual property licensing arrangement with Plexxikon for bezuclastinib, indicating IP licensing activity.
|
$1.85B |
$16.27
|
|
Licenses intellectual property (franchises/IP) to partners, broadening IP monetization.
|
$1.75B |
$6.13
-0.33%
|
|
Adeia primarily derives revenue from licensing its extensive patent portfolio and IP assets to customers, i.e., Intellectual Property Licensing.
|
$1.70B |
$15.71
-4.32%
|
|
Intellectual Property Licensing – monetizing IMAX IP/brand and proprietary processes (e.g., Filmed For IMAX) with partners.
|
$1.68B |
$31.20
-3.76%
|
|
Intellectual property licensing of software and IP assets to customers and partners.
|
$1.65B |
$39.26
+1.00%
|
|
Biogen collaboration provides a substantial upfront IP licensing payment and milestone potential, a major revenue stream.
|
$1.65B |
$30.19
-2.46%
|
|
Intellectual property licensing is central to Falcons Beyond’s strategy, monetizing IP across brands and partnerships.
|
$1.53B |
$12.65
-0.86%
|
|
Licensing of IP assets (e.g., Disney IP) falls under Intellectual Property Licensing.
|
$1.27B |
$3.39
-4.78%
|
|
LENZ generates revenue through licensing agreements for its IP internationally, representing Intellectual Property Licensing as a core business activity.
|
$1.09B |
$38.79
-17.03%
|
|
Licensing of electrolyte technology and related cell manufacturing know-how constitutes Intellectual Property Licensing.
|
$1.05B |
$5.86
-2.66%
|
|
Zenas licenses IP for obexelimab/ZB assets and derives upfront licensing revenue
|
$963.44M |
$23.03
+5.84%
|
|
Technology-as-a-Service model emphasizes co-developing differentiated IP and potential IP licensing with customers.
|
$868.51M |
$18.08
+11.95%
|
|
Intellectual property licensing revenue suggests Build-A-Bear licenses its IP to third parties beyond direct product sales.
|
$791.86M |
$59.95
+0.57%
|
|
NP Power licenses its Net Power Cycle technology, representing IP licensing as a core business model.
|
$740.45M |
$3.70
+9.47%
|
|
Scholastic leverages its IP across licensing arrangements, representing an IP licensing stream beyond traditional publishing.
|
$703.90M |
$28.10
-3.50%
|
|
The company is pursuing out-licensing of Anaphylm and IP monetization, indicating Intellectual Property Licensing as a revenue/asset strategy.
|
$649.60M |
$6.54
-2.24%
|
|
LWLG monetizes via licensing its electro‑optic polymer technology, including IP licensing.
|
$648.96M |
$5.19
-13.14%
|
|
CEVA's core business model is IP licensing and royalty generation from its portfolio of DSP/NPU and wireless IP.
|
$622.54M |
$26.04
+0.04%
|
|
Butterfly licenses its chip technology and IP through Octiv, creating an IP licensing revenue stream.
|
$563.82M |
$2.28
-10.59%
|
|
Strategic licensing of NAV technology and upfront/license revenue indicate Intellectual Property Licensing is a core revenue/distribution channel.
|
$547.75M |
$10.92
-9.83%
|
|
Lexicon licenses key assets (LX9851 to Novo Nordisk and sotagliflozin outside the U.S./Europe via Viatris), representing a material IP licensing activity.
|
$541.14M |
$1.49
-10.24%
|
|
Licensing of proprietary IP (platforms like AI XPLR/ZBrain) through a JV creates an Intellectual Property Licensing line.
|
$533.47M |
$19.29
-0.16%
|
|
Licensing of B-Vault hardware/software architecture indicates IP licensing as a revenue stream.
|
$521.19M |
$3.34
-4.57%
|
|
Cerence licenses its AI software and IP to OEMs/partners, representing Intellectual Property Licensing activity.
|
$515.64M |
$11.92
+6.81%
|
|
The company discusses monetizing IP/assets and potentially licensing, aligning with Intellectual Property Licensing.
|
$505.27M |
$8.76
-12.40%
|
|
Intellectual property licensing of music IP to partners and users as a revenue stream.
|
$496.30M |
$7.60
-0.91%
|
|
XOMA Royalty's primary business is the licensing of economic rights and IP-backed revenue streams from partnered therapies.
|
$435.95M |
$36.43
-5.99%
|
|
Licensing of intellectual property beyond the brand (IP Licensing) is a direct revenue stream.
|
$427.23M |
$104.47
-2.10%
|
|
LOI to license Rain Cage Carbon technology constitutes Intellectual Property Licensing of new tech.
|
$409.59M |
$9.00
|
|
Licensing of Value Line's proprietary data and ranking system IP to clients and partners.
|
$361.80M |
$38.45
-2.92%
|
|
AMC Networks monetizes its owned IP library through licensing arrangements across platforms and distributors.
|
$337.85M |
$7.52
-5.05%
|
|
Core revenue is derived from licensing and monetizing patent portfolios via Acacia's IP licensing operation.
|
$323.14M |
$3.36
-2.61%
|
|
Intellectual property licensing related to TALEN technology (e.g., IOva/Iovance collaboration).
|
$291.26M |
$4.04
-3.81%
|
|
Xperi licenses its IP/software platforms (e.g., TiVo OS, ad platform) to partners.
|
$287.37M |
$6.29
-6.26%
|
|
The company licenses the NIH anti-CD19 CAR IP, representing its IP licensing activity.
|
$286.54M |
$6.63
-5.69%
|
|
Licensing of intellectual property to third parties (IP licensing for games).
|
$280.22M |
$2.22
-11.55%
|
|
Licensing of IP (e.g., UC San Diego, Oncotelic) indicates Intellectual Property Licensing activity.
|
$280.13M |
$0.70
|
|
Strategic licensing of core tech/IP (e.g., TALEN) with third parties; IP licensing is a direct business activity.
|
$269.04M |
$1.23
-14.58%
|
|
The company engages in licensing of its IP/assets with partners (e.g., in China, Japan, and South Korea), generating milestone payments and royalties.
|
$238.77M |
$4.55
-6.19%
|
|
Significant revenue from IP licensing and IP monetization, including RAD-Hard and related agreements.
|
$238.38M |
$10.61
-8.30%
|
|
BDTX licensed IP (BDTX-4933) to Servier, signaling active intellectual property licensing as a revenue/strategy component.
|
$232.57M |
$4.09
-6.41%
|
|
Possesses a substantial patent portfolio and licensing of core technology, indicating Intellectual Property Licensing activity.
|
$219.38M |
$11.53
-1.11%
|
|
Licensing of the J-J Hook technology indicates an Intellectual Property Licensing revenue stream.
|
$182.37M |
$34.38
-0.92%
|
|
SRM engages in intellectual property licensing of IP assets to produce licensed merchandise for theme parks and related venues.
|
$177.61M |
$10.30
+53.27%
|
|
Innventure licenses IP from multinational corporations and monetizes it through technology licensing, aligning with Intellectual Property Licensing.
|
$171.43M |
$3.46
-24.78%
|
|
Journey Medical engages in intellectual property licensing and out-licensing of dermatology assets, including Emrosi IP portfolio.
|
$169.83M |
$7.29
+0.41%
|
|
Silvaco provides semiconductor SIP (IP) as a core offering.
|
$166.62M |
$5.67
+2.72%
|
|
Partnership-driven licensing of intellectual property to users/partners reflects IP Licensing activity.
|
$144.13M |
$2.76
-7.69%
|
|
Licensing of CAR-T and vaccine technologies/IP to partners represents Intellectual Property Licensing activity.
|
$139.47M |
$4.33
-12.35%
|
|
Licensing of DVLT’s IP/assets (Data Vault, Adio) and its 72+ patent portfolio supports Intellectual Property Licensing.
|
$125.45M |
$1.90
-13.64%
|
|
Ownership and licensing of game IP assets and related technology.
|
$118.20M |
$0.94
+0.52%
|
|
Licensing revenue from collaborations (AffaMed, Fuji Pharma) indicating IP licensing activities.
|
$117.51M |
$4.03
-4.73%
|
|
HB4 trait licensing represents Intellectual Property Licensing.
|
$89.87M |
$1.43
-1.38%
|
|
Intellectual property licensing related to AMTD's brand assets and media properties.
|
$86.30M |
$1.08
-2.25%
|
|
Zentek is an IP technology developer/commercializer with licensing as a core business activity.
|
$81.22M |
$0.78
-0.42%
|
|
Strategic out-licensing of platforms and IP (to Debiopharm and DCx Biotherapeutics) aligns with IP licensing as a revenue/financing mechanism.
|
$77.20M |
$1.80
-1.10%
|
|
Patented IP portfolio enables intellectual property licensing as a revenue stream.
|
$69.94M |
$16.50
-2.43%
|
|
Intellectual Property Licensing – Adjacent IP licensing opportunities mentioned in strategy.
|
$68.20M |
$12.52
-3.69%
|
|
The company engages in IP licensing and collaboration agreements with partners (e.g., Imugene, Novartis, TG Therapeutics), signaling licensing of IP as a core business activity.
|
$62.87M |
$5.67
+4.23%
|
|
Intellectual property licensing activity related to regRNA platform with collaborators (e.g., Fulcrum, BioMarin).
|
$61.09M |
$3.03
+1.00%
|
|
Company licenses its intellectual property (IP) broadly, including Hasbro brands, a core IP licensing business.
|
$60.71M |
$2.75
-2.14%
|
|
LNZA licenses its gas fermentation technology and IP, aligning with an intellectual property licensing model.
|
$60.68M |
$26.16
-9.61%
|
|
Neonode's core business is licensing its intellectual property (zForce, MultiSensing) to customers, generating IP licensing revenue.
|
$59.24M |
$3.53
-7.11%
|
|
Phunware is pursuing patent monetization and IP licensing related to its technology, aligning with IP Licensing.
|
$56.88M |
$2.82
-6.00%
|
|
Netlist actively monetizes its patent portfolio through licensing and enforcement, i.e., Intellectual Property Licensing.
|
$56.55M |
$0.64
-3.36%
|
|
Promoter license and media rights constitute intellectual property assets that could be licensed or monetized.
|
$52.58M |
$1.79
|
|
The company monetizes its IP portfolio (Q-Cup, Imitine) via licensing and enforcement actions, fitting Intellectual Property Licensing.
|
$48.13M |
$0.00
|
|
VolitionRx monetizes through licensing its Nu.Q platform technology (Intellectual Property Licensing).
|
$47.81M |
$0.46
-10.75%
|
|
RMCO holds royalty rights on intellectual property (e.g., PGM Technology) and licenses associated revenues.
|
$46.16M |
$3.09
-5.21%
|
|
RPMT monetizes its proprietary technology via licensing, i.e., Intellectual Property Licensing.
|
$45.97M |
$0.37
-1.75%
|
|
Licensing of gene-edited traits to seed companies with royalty streams.
|
$44.36M |
$1.29
-0.77%
|
|
Company owns/ licenses software IP related to the KB Platform (copyrights), reflecting IP Licensing.
|
$43.31M |
$1.76
-3.55%
|
|
Intellectual property licensing for Stan Lee Universe and related IP assets.
|
$36.61M |
$0.77
-3.04%
|
|
Enzo monetizes its intellectual property via licensing arrangements and IP asset monetization.
|
$36.59M |
$0.70
|
|
Licensing of intellectual property/assets broadly to partners; strategic IP exploitation beyond games.
|
$31.77M |
$0.84
-7.04%
|
|
Kezar's Everest Medicines collaboration involves licensing of IP assets, fitting Intellectual Property Licensing.
|
$30.83M |
$4.22
-5.17%
|
|
Allarity licenses IP related to its DRP algorithms and platform to partners.
|
$24.28M |
$1.61
-8.52%
|
|
APHP’s core activity centers on owning or optioning IP rights and monetizing via licensing arrangements, fitting Intellectual Property Licensing.
|
$19.83M |
$0.18
|
|
NAII licenses its beta-alanine patent portfolio (CarnoSyn, SR CarnoSyn, TriBsyn), generating IP licensing revenue.
|
$16.44M |
$2.66
-3.28%
|
|
The company owns Le Mans IP and other licenses, monetizing them through IP licensing arrangements.
|
$13.98M |
$2.42
-5.84%
|
Showing page 1 of 2 (126 total stocks)
Loading industry metrics...
Loading comparison data...
